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ABSTRACT. Multiple endocrine neoplasia 2A (MEN 
2A) is an inherited dominant syndrome charac-
terised by medullary thyroid carcinoma, adrenal 
pheochromocytoma and hyperparathyroidism due 
to specific RET proto-oncogene mutations. Fertile 
MEN 2A women are at risk of complicated pregnan-
cy because of unrecognised pheochromocytoma 
and transmission of RET mutation to the progeny. 
This condition may cause physiological distress in af-
fected pregnant patients and their families. Here we 
describe the genetic prenatal testing, the pregnan-
cy management and obstetric outcome in a MEN 
2A patient with a right side adrenal hyperplasia and 
elevated calcitonin levels, a condition suspicious 
for possible recurrence of pheochromocytoma. 
We confirm that maternal or fetal complications 
are rare when MEN 2A diagnosis is made before 
pregnancy and an accurate monitoring is instituted. 
Furthermore, our results indicate that prenatal test-
ing for RET mutations is highly recommended in 
making decisions and assuring parents on the life-
long risk of tumors. This will avoid the psychological 
distress that can further complicate the pregnancy 
of affected women.
(J. Endocrinol. Invest. 27: ??-??, 2004)
©2004, Editrice Kurtis
INTRODUCTION 
Multiple endocrine neoplasia 2A (MEN 2A) is an in-
herited dominant cancer syndrome characterised by 
medullary thyroid carcinoma (MTC), adrenal pheo-
chromocytoma and hyperparathyroidism (1). Related 
to this syndrome are MEN 2B, which includes MTC, 
pheochromocytoma, neurogangliomatosis and a 
marfanoid habitus, and familial medullary thyroid car-
cinoma (FMTC), in which the MTC is the sole clinical 
manifestation (1). Specific RET proto-oncogene muta-
tions are associated with all three clinical entities: co-
don 634 is affected in most MEN 2A cases; codon 918 
is almost uniquely altered in MEN 2B, whereas in FMTC 
more heterogeneous mutations have been described 
(2, 3). Pheochromocytoma is present in more than 50% 
of MEN 2A patients, but its frequency is probably un-
derestimated, because it develops later in the follow-
up and/or may be asymptomatic (4). Although classic 
features of pheochromocytoma are paroxysmal hyper-
tensive crises or sustained hypertension with increased 
normetanephrine and/or metanephrine levels, most 
patients are in fact asymptomatic or have non-specific 
clinical manifestations and basal hormonal evaluation 
in the normal range (5). Fertile affected women are at 
high risk of complicated pregnancy because of the 
transfer of the mutated genetic trait to the progeny and 
the presence or development of pheochromocytoma 
that may render the pregnancy outcome or delivery 
difficult, resulting in high maternal and/or fetal mortal-
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ity (6, 7). Prenatal diagnosis and correct management 
of pheochromocytoma greatly improve survival and 
pregnancy outcome (6). Moreover, the RET test and 
the identification of specific mutations allow appropri-
ate genetic counselling and prenatal diagnosis, avoid-
ing psychological distress in affected pregnant patients 
and their families. Here we discuss the genetic prenatal 
testing and pregnancy management in a MEN 2A pa-
tient together with a reviewing of the literature. 
CASE REPORT
A 31-yr-old primigravid woman affected by MEN 2A 
syndrome came to our Department for care at the 
7th week of gestation. Detailed clinical description 
and genetic analysis have previously been reported 
(8). She had undergone total thyroidectomy (at 27 
yr old) because of a MTC. Six months later she was 
hospitalised for hypertension, high plasma calcitonin 
levels and urinary catecholamine levels and underwent 
left adrenalectomy for ipsilateral pheochromocytoma. 
These features were in agreement with the diagnosis 
of MEN 2A with a peculiar clinical picture represented 
by MTC, calcitonin-producing pheochromocytoma 
and no involvement of the parathyroid glands (8). Mo-
lecular analysis of the RET gene disclosed an unusual 
condition with two RET mutations at codons 634 and 
640, on two separate alleles. Endocrine evaluations 
performed before the pregnancy showed periodic 
upper-normal levels of catecholamines, increased 
calcitonin levels, normal calcium, phosphate and PTH 
(Table 1); ultrasound scan and computerized tomogra-
phy revealed a hypertrophic right adrenal gland. In this 
peculiar case, elevated calcitonin (CT) levels and the 
right adrenal hyperplasia were suspicious for a pheo-
chromocytoma recurrence in the right side. A gluca-
gon test (1 mg ev) induced a near two-fold increase in 
plasma norepinephrine (115 to 226 pg/ml) and epine-
phrine (58 to 120 pg/ml), while heart rate and blood 
pressure were unchanged (72 and 110/80 before, 81 
and 125/80 after). These data are consistent with no 
increased secretory activity from the hypertrophic right 
adrenal gland. Genetic counselling was provided and 
prenatal diagnosis for this new genetic variant of MEN 
2A and for karyotype analysis was performed at the 11th 
week by chorionic villus sampling. The genetic analysis 
was carried out at the Department of Biochemistry and 
Medical Biotechnologies and Laboratory Medicine at 
the Medical School of the University of Naples Fed-
erico II, that is a reference centre for MEN 2 diagnosis 
for the entire region. All procedures were carried out 
after having obtained informed consent from the 
patient. The genetic test was performed on the DNA 
extracted from the chorionic villi and amplified by PCR 
using specific primers for RET exon 11. The PCR prod-
uct was subsequently sequenced on both strands and 
the result excluded the presence of any RET mutation 
as those present in the mother’s DNA. The result was 
confirmed by restriction enzyme digestion carried on 
the PCR amplified product. Karyotype analysis showed 
a 46XX value, without numerical and structural chro-
mosome abnormalities. The patient maintained an 
euthyroid state, with 125 µg daily of oral levothyroxine 
and her blood pressure remained under 140/90 mmHg 
during pregnancy; urinary and plasma glycaemia, liver 
enzymes and electrolyte levels were also in the normal 
range throughout pregnancy. Urinary excretion of 
metanephrine was normal (Table 1). Plasma calcitonin 
levels remained elevated. The patient did not experi-
ence headache, tachycardia, irritability or edema. 
Ultrasound fetal examination showed normal growth. 
The patient underwent cesarean delivery at 39 weeks: 
the infant weighed 3590 g, with 1 and 5 min Apgar 
scores of 9 and 9. During surgery maternal blood pres-
sure remained under 140/90 mmHg. 
COMMENTS
Pheochromocytoma is a rare cause of secondary 
hypertension with an estimated incidence of 0.1% 
in the population affected by hypertension (9). As-
sociation of pheochromocytoma with pregnancy is 
Table 1 - Laboratory findings before, during pregnancy, and at delivery.
Parameter Before pregnancy 1st trim 2nd trim 3rd trim Delivery Normal range
Urinary epinephrine
(µg/ml.24h)
10-14* 11 7.2 8 14.2 0-15
Urinary norepinephrine
(µg/ml.24h)
81-95* 75 44.5 72 60 0-100
Urinary vanillylmandelic
acid (mg/ml.24h)
4 5 3.2 3.6 3.8 2-7
Serum CT (pg/ml) 320 500 429 370 0-15
Serum PTH (pg/ml) 18 22 10-60
Serum TSH (µU/ml) 0.2 0.2 0.2-3.5
*: report of two observations; CT: calcitonin.
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very rare, but its occurrence is responsible for high 
maternal and/or fetal mortality (7). It has recently 
been shown that prenatal diagnosis and correct 
management greatly improve survival and outcome 
drastically reducing maternal (1 vs 19%) and fetal (12 
vs 25%) mortality (6). MEN 2A women are at risk of 
complicated pregnancy because of unrecognised 
pheochromocytoma. This tumor develops in more 
than 50% of MEN 2A patients and occurs bilaterally 
in nearly 50% of cases. However, the real incidence 
is underestimated because of the late occurrence of 
this neoplasia and because MEN 2A patients with a 
recognised MTC are not followed up for long time 
(4, 5). Pheochromocytoma is usually characterised 
by paroxysmal or sustained hypertension, headache, 
sweating, palpitation and skin pallor. Hypertensive 
crises, symptoms such as palpitations, nausea, 
sweating, headache, anxiety and depression, on the 
other hand, may be present in a normal pregnancy, 
due to a number of different causes. Basal hormonal 
evaluation may also be in the normal range (4). The 
correct diagnosis may then be difficult. Pheochro-
mocytoma was, in fact, described as the “great 
mimic” for the numerous subjective manifestations 
and may be responsible for frequent psychiatric 
manifestations. Urinary metanefrine measurements 
and abdominal ultrasonography are the most useful 
tools for the diagnosis and localisation of pheochro-
mocytoma also during pregnancy. However, basal 
urinary catecholamine excretion may be normal in 
many patients and tumor mass may be intra-adrenal. 
An altered epinephrine/norepinephrine ratio in 24-h 
collection and glucagon test have been suggested 
to improve the diagnostic sensitivity of catecho-
lamine measurement (4, 9-11).
In the present case, adrenal hyperplasia and elevated 
CT levels could suggest a possible recurrence of a 
right side pheochromocytoma. In this patient we 
previously showed that the pheochromocytoma tu-
mor expressed and secreted authentic calcitonin (8). 
Thus high calcitonin values after total thyroidectomy 
in absence of residual thyroid tissue, metastasised 
nodes and tissues, could indicate an unrecognised 
hyperplasia or recurrence of a medullary gland tumor. 
However, normal epinephrine/norepinephrine ratio 
and glucagon test performed before the pregnancy 
were both consistent with normal residual medullary 
function. The periodic assessment of urinary metane-
phrine and catecholamines and abdominal sonogra-
phy scan together with normal clinical features (heart 
rate, blood pressure) reassured that pheochromocy-
toma did not recur during pregnancy and allowed 
us to plan a cesarean section without antiadrenergic 
pharmacological preparation. There is no general 
agreement on how to carry out the delivery (6, 12-14). 
We chose a cesarean section because the patient was 
primigravid and, as suggested by most authors, this 
method assures the control of delivery conditions. 
During pregnancy, therapy of pheochromocytoma 
was based on medical therapy with α-blockers to 
control maternal blood pressure. The α-blockers phe-
nossibenzamine, prazosine or doxazosine are usually 
employed since none of these have any adverse reac-
tions to the fetus or to the mother (14). 
Reports of pregnancy outcome in MEN 2A patients 
are rare. Complications consisted of maternal or fe-
tal death for hypertensive crisis due to sequelae of 
elevated catecholamine levels secreted from unrec-
ognised pheochromocytoma. A maternal-fetal death 
for hypertensive crisis at 22 weeks (15) and a patient 
with hypertension, a right intracerebral hemorrhage 
at 35 weeks and residual neurologic deficits (16) have 
been described. When MEN 2A diagnosis precedes 
pregnancy and there is no incidence of pheochromo-
cytoma, the pregnancy can proceed without mater-
nal or fetal complications (17-19). 
Another point to discuss is the importance of the ge-
netic counselling and prenatal diagnosis in MEN 2A 
patients. Because it is an autosomally dominant dis-
ease, it manifests itself in a heterozygous condition, 
i.e. a single mutation in one RET allele is sufficient to 
develop the disease. Fifty percent of the progeny 
thus risks inheriting the mutation and developing 
the disease. RET mutations, moreover, have been 
associated with 3 risk levels from MTC and pheochro-
mocytoma (20). RET codon 634 mutation, as the one 
described in the present case, is considered a level 
2, with a high risk for MTC and justifies prophylactic 
total thyroidectomy before 5 yr of age. Moreover, 
pheochromocytoma has been associated with codon 
634 mutation as early as 5 and 10 yr of age. Therefore, 
genetic prenatal testing for RET mutations is manda-
tory, even if risk and benefits should be discussed (20). 
A literature search showed only one report of prenatal 
diagnosis of RET proto-oncogene mutations in MEN 
2A patients (21). Using chorionic villi as starting mate-
rials and the PCR and DNA sequencing test, we ex-
cluded that the fetus was bearing the same maternal 
mutation of RET protooncogene at 11 weeks. 
In conclusion, pregnancy complicated by pheochro-
mocytoma in MEN 2A is rarely described. The litera-
ture confirms that early diagnosis and collaboration 
between obstetricians, endocrinologists, anaesthesi-
ologists and molecular biologists prevent the serious 
maternal and fetal complications associated with 
hypertensive crises. Prenatal testing for RET mutation 
and appropriate counselling are important in making 
decisions and assuring parents on the life-long risk of 
tumors, avoiding psychological distress that can fur-
ther complicate pregnancy in affected women.
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